secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-03-18T23:59:59+00:00
Accession:  0001564590-22-011090
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD receives Nasdaq delisting notice for bid price non-compliance; CFO resigns
--------------------------------------------------------------------------------

- Received Nasdaq delisting notice on March 15, 2022 for failing to maintain $1.00 minimum bid price within 180-day compliance period.
- Company requested a hearing to appeal; trading stay pending Panel decision.
- Intends to consider reverse stock split to regain compliance with minimum bid price requirement.
- CFO James C. D'Arecca resigns effective April 1, 2022; Michael C. Donegan appointed Interim CFO.
- Search for permanent CFO initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/0001564590-22-011090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/txmd-8k_20220314.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-011090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer